Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 3/2012

01.12.2012

Single-chamber ICD, single-zone therapy in primary and secondary prevention patients: the simpler the better?

verfasst von: S. González-Enríquez, F. Rodríguez-Entem, V. Expósito, C. Castrillo-Bustamante, A. Canteli, A. Solloso, I. Madrazo, J. J. Olalla

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

It is now well established that implantable cardioverter defibrillator (ICD) implantation reduces mortality in patients at increased risk of sudden cardiac death. However, the best programming parameters remain controversial. Our traditional policy has followed a simple approach in the vast majority of patients. In accordance with ICD programming in the major randomized clinical trials, we programmed a single high-rate, shock-only therapy zone. We aimed to demonstrate in this observational study that simple programming is not associated with higher shock rates or mortality when compared to other published studies.

Methods

Consecutive patients who underwent single-chamber ICD implantation with single-zone, high-rate programming at our institution between 1993 and 2008 were retrospectively studied. Data were collected prospectively in a database regarding details of ICD implantation, demographic data, and indication.

Results

Three hundred thirty-two patients were included in our study, 31 % primary prevention and 68 % secondary prevention. Mean ejection fraction (EF) is 33.7 ± 15.3. Over a mean follow-up period of 62.5 ± 38.1 months, 135 patients experienced ICD shock (annualized event rate 7.7 %); 89 patients (26.8 %) appropriate shock in VT–ventricular fibrillation (VF), 68 patients (20.5 %) inappropriate shocks, and 22 patients (6.6 %) both. Twenty-nine patients (8.7 %) were reprogrammed to additional VT–ATP zones. Twenty-two (6.6 %) patients underwent heart transplantation. Sixty-two patients (18.6 %) died during follow-up, 43.6 % out of them due to cardiac cause, mainly progressive heart failure.

Conclusion

Our results show that simpler settings with single-zone, high-rate programming is associated with ICD shock rates and long-term mortality that does not appear to be worse when compared with contemporary studies which include multizone ICD programming with antitachycardia pacing activated.
Literatur
1.
Zurück zum Zitat Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine, 346, 877–883.CrossRef Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine, 346, 877–883.CrossRef
2.
Zurück zum Zitat Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., et al. (2005). Sudden cardiac death in heart failure trial (SCD-HeFT) investigators. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. The New England Journal of Medicine, 352, 225–237.CrossRef Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., et al. (2005). Sudden cardiac death in heart failure trial (SCD-HeFT) investigators. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. The New England Journal of Medicine, 352, 225–237.CrossRef
3.
Zurück zum Zitat The Antiarrhythmic versus Implantable cardioverter Defibrillators (AVID) Investigators. (1997). A comparison of antiarrhythmic-drug therapy with implantable cardioverter defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England Journal of Medicine, 337, 1576–1583.CrossRef The Antiarrhythmic versus Implantable cardioverter Defibrillators (AVID) Investigators. (1997). A comparison of antiarrhythmic-drug therapy with implantable cardioverter defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England Journal of Medicine, 337, 1576–1583.CrossRef
4.
Zurück zum Zitat Hohnloser, S. H., Kuck, K. H., Dorian, P., Roberts, R. S., Hamptom, J. R., Hatala, R., et al. (2004). DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. The New England Journal of Medicine, 351, 2481–2488.CrossRef Hohnloser, S. H., Kuck, K. H., Dorian, P., Roberts, R. S., Hamptom, J. R., Hatala, R., et al. (2004). DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. The New England Journal of Medicine, 351, 2481–2488.CrossRef
5.
Zurück zum Zitat Goldenberg, I., Moss, A. J., Hall, W. J., McNitt, S., Zareba, W., & Andrews, M. L. (2006). Cannom DS; Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the Multicenter Automatic Defibrillator Implantation Trial II. Circulation, 113, 2810–2817.CrossRef Goldenberg, I., Moss, A. J., Hall, W. J., McNitt, S., Zareba, W., & Andrews, M. L. (2006). Cannom DS; Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the Multicenter Automatic Defibrillator Implantation Trial II. Circulation, 113, 2810–2817.CrossRef
6.
Zurück zum Zitat Daubert, J. P., Zareba, W., Cannom, D. S., McNitt, S., Rosero, S. Z., Wanq, P., et al. (2008). Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors and survival impact. Journal of the American College of Cardiology, 51, 1357–1365.CrossRef Daubert, J. P., Zareba, W., Cannom, D. S., McNitt, S., Rosero, S. Z., Wanq, P., et al. (2008). Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors and survival impact. Journal of the American College of Cardiology, 51, 1357–1365.CrossRef
7.
Zurück zum Zitat Poole, J. E., Johnson, G. W., Hellkamp, A. S., Anderson, J., Callans, D. J., Raitt, M. H., et al. (2008). Prognostic importance of defibrillator shocks in patients with heart failure. The New England Journal of Medicine, 359, 1009–1017.CrossRef Poole, J. E., Johnson, G. W., Hellkamp, A. S., Anderson, J., Callans, D. J., Raitt, M. H., et al. (2008). Prognostic importance of defibrillator shocks in patients with heart failure. The New England Journal of Medicine, 359, 1009–1017.CrossRef
8.
Zurück zum Zitat Sweeney, M. O., Sherfesee, L., DeGroot, P. J., Wathen, M. S., & Wikoff, B. L. (2010). Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm, 7, 353–360.CrossRef Sweeney, M. O., Sherfesee, L., DeGroot, P. J., Wathen, M. S., & Wikoff, B. L. (2010). Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm, 7, 353–360.CrossRef
9.
Zurück zum Zitat Kapa, S., Rotondi-Trevisan, D., Mariano, Z., Aves, T., Irvine, J., Dorian, P., et al. (2010). Psychopathology in patients with ICD over time: results of a prospective study. Pacing and Clinical Electrophysiology, 33, 198–208.CrossRef Kapa, S., Rotondi-Trevisan, D., Mariano, Z., Aves, T., Irvine, J., Dorian, P., et al. (2010). Psychopathology in patients with ICD over time: results of a prospective study. Pacing and Clinical Electrophysiology, 33, 198–208.CrossRef
10.
Zurück zum Zitat Duru, F., Buchi, S., Klaghofer, R., Mattmann, H., Sensky, T., Buddeberg, C., et al. (2001). How different from pacemaker patients are recipients of implantable cardioverter-defibrillators with respect to psychosocial adaptation, affective disorders, and quality of life? Heart, 85, 375–379.CrossRef Duru, F., Buchi, S., Klaghofer, R., Mattmann, H., Sensky, T., Buddeberg, C., et al. (2001). How different from pacemaker patients are recipients of implantable cardioverter-defibrillators with respect to psychosocial adaptation, affective disorders, and quality of life? Heart, 85, 375–379.CrossRef
11.
Zurück zum Zitat Schron, E. B., Exner, D. V., Yao, Q., Jenkins, L. S., Steinberg, J. S., Cook, J. R., et al. (2002). Quality of life in the antiarrhythmic versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillators shocks. Circulation, 105, 589–594.CrossRef Schron, E. B., Exner, D. V., Yao, Q., Jenkins, L. S., Steinberg, J. S., Cook, J. R., et al. (2002). Quality of life in the antiarrhythmic versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillators shocks. Circulation, 105, 589–594.CrossRef
12.
Zurück zum Zitat Kadish, A., Dyer, A., Daubert, J. P., Quiqq, R., Estes, N. A., Anderson, K. P., et al. (2004). Defibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE) investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. The New England Journal of Medicine, 350, 2151–2158.CrossRef Kadish, A., Dyer, A., Daubert, J. P., Quiqq, R., Estes, N. A., Anderson, K. P., et al. (2004). Defibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE) investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. The New England Journal of Medicine, 350, 2151–2158.CrossRef
13.
Zurück zum Zitat Wathen, M. S., Sweeney, M. O., DeGroot, P., Stark, A. J., Koehler, J. L., Chisner, M. B., et al. (2001). Shock reduction using antitachycardia pacing for rapid spontaneous ventricular tachycardia in patients with coronary artery disease. Circulation, 104, 796–801.CrossRef Wathen, M. S., Sweeney, M. O., DeGroot, P., Stark, A. J., Koehler, J. L., Chisner, M. B., et al. (2001). Shock reduction using antitachycardia pacing for rapid spontaneous ventricular tachycardia in patients with coronary artery disease. Circulation, 104, 796–801.CrossRef
14.
Zurück zum Zitat Wathen, M. S., DeGroot, P. J., Sweeney, M. O., Stark, A. J., Otterness, M. F., Adkisson, W. O., et al. (2004). Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter defibrillators. PainFREE Rx II Trial Results. Circulation, 110, 2592–2596.CrossRef Wathen, M. S., DeGroot, P. J., Sweeney, M. O., Stark, A. J., Otterness, M. F., Adkisson, W. O., et al. (2004). Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter defibrillators. PainFREE Rx II Trial Results. Circulation, 110, 2592–2596.CrossRef
15.
Zurück zum Zitat Wilkoff, B. L., Ousdigian, K. T., Sterns, L. D., Wanq, Z. J., Wilson, R. D., & Morgan, J. M. (2006). A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: Results from the prospective randomized multicenter EMPIRIC trial. Journal of the American College of Cardiology, 48, 330–339.CrossRef Wilkoff, B. L., Ousdigian, K. T., Sterns, L. D., Wanq, Z. J., Wilson, R. D., & Morgan, J. M. (2006). A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: Results from the prospective randomized multicenter EMPIRIC trial. Journal of the American College of Cardiology, 48, 330–339.CrossRef
16.
Zurück zum Zitat Wilkoff, B., Williamson, B., Stern, R., Moore, S., Lu, F., Lee, S., et al. (2008). Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) Study. Journal of the American College of Cardiology, 52, 541–550.CrossRef Wilkoff, B., Williamson, B., Stern, R., Moore, S., Lu, F., Lee, S., et al. (2008). Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) Study. Journal of the American College of Cardiology, 52, 541–550.CrossRef
17.
Zurück zum Zitat Epstein, A. E., Dimarco, J. P., Ellenbogen, K. A., & Estes, N. A., III. (2008). Freedman RA, Gettes LS et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm, 5, e1–e62.CrossRef Epstein, A. E., Dimarco, J. P., Ellenbogen, K. A., & Estes, N. A., III. (2008). Freedman RA, Gettes LS et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm, 5, e1–e62.CrossRef
18.
Zurück zum Zitat Duncan, E., Thomas, G., Neville, J., Pfeffer, C., Appanna, G., Shah, N., et al. (2010). Do traditional VT zones improve outcome in primary prevention ICD patients? PACE, 33, 1353–1358.CrossRef Duncan, E., Thomas, G., Neville, J., Pfeffer, C., Appanna, G., Shah, N., et al. (2010). Do traditional VT zones improve outcome in primary prevention ICD patients? PACE, 33, 1353–1358.CrossRef
19.
Zurück zum Zitat Gulizia, M., Piraino, L., Scherillo, M., Puntrello, C., Vasco, C., Scianaro, M. C., et al. (2009). A randomized study to compare ramp versus burst antitachycardia pacing therapies to treat fast ventricular tachyarrhythmia in patients with implantable cardioverter defibrillators: The PITAGORA ICD Trial. Circulatory Arrhythmia Electrophysiology, 2, 146–153.CrossRef Gulizia, M., Piraino, L., Scherillo, M., Puntrello, C., Vasco, C., Scianaro, M. C., et al. (2009). A randomized study to compare ramp versus burst antitachycardia pacing therapies to treat fast ventricular tachyarrhythmia in patients with implantable cardioverter defibrillators: The PITAGORA ICD Trial. Circulatory Arrhythmia Electrophysiology, 2, 146–153.CrossRef
20.
Zurück zum Zitat Santini, M., Lunati, M., Defaye, P., Mermi, J., Proclemer, A., del Castillo-Arroys, S., et al. (2010). Prospective multicenter randomized trial of fast ventricular tachycardia termination by prolonged versus conventional anti-tachycardia burst pacing in implantable cardioverter-defibrillator patients-Atp DeliVery for pAiNless ICD therapy (ADVANCE-D) Trial results. Journal of Interventional Cardiac Electrophysiology, 27, 127–135.CrossRef Santini, M., Lunati, M., Defaye, P., Mermi, J., Proclemer, A., del Castillo-Arroys, S., et al. (2010). Prospective multicenter randomized trial of fast ventricular tachycardia termination by prolonged versus conventional anti-tachycardia burst pacing in implantable cardioverter-defibrillator patients-Atp DeliVery for pAiNless ICD therapy (ADVANCE-D) Trial results. Journal of Interventional Cardiac Electrophysiology, 27, 127–135.CrossRef
21.
Zurück zum Zitat Germano, J., Reynolds, M., Essebag, V., & Josephson, M. (2006). Frequency and causes of implantable cardioverter-defibrillator therapies: Is device therapy proarrhythmic? The American Journal of Cardiology, 97, 1255–1261.CrossRef Germano, J., Reynolds, M., Essebag, V., & Josephson, M. (2006). Frequency and causes of implantable cardioverter-defibrillator therapies: Is device therapy proarrhythmic? The American Journal of Cardiology, 97, 1255–1261.CrossRef
22.
Zurück zum Zitat Volosin, K. J., Exner, D. V., Wathen, M. S., Sherfesse, L., Scinicariello, A. P., & Gillberg, J. M. (2011). Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling. Journal of Cardiovascular Electrophysiology, 22(3), 280–289.CrossRef Volosin, K. J., Exner, D. V., Wathen, M. S., Sherfesse, L., Scinicariello, A. P., & Gillberg, J. M. (2011). Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling. Journal of Cardiovascular Electrophysiology, 22(3), 280–289.CrossRef
23.
Zurück zum Zitat Sweeney, M., Wathen, M., Volosin, K., Abdalla, I., DeGroot, P. J., Otterness, F., et al. (2005). Appropriate and inappropriate ventricular therapies, quality of life and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT Reduces Shock Therapies (PainFREE Rx II) trial. Circulation, 111, 2898–2905.CrossRef Sweeney, M., Wathen, M., Volosin, K., Abdalla, I., DeGroot, P. J., Otterness, F., et al. (2005). Appropriate and inappropriate ventricular therapies, quality of life and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT Reduces Shock Therapies (PainFREE Rx II) trial. Circulation, 111, 2898–2905.CrossRef
24.
Zurück zum Zitat Rosenqvist, M., Beyer, T., Block, M., den Dulk, K., Minten, J., & Lindermans, F. (1998). Adverse events with transvenous implantable cardioverter-defibrillators. A prospective multicenter study. Circulation, 98, 663–670.CrossRef Rosenqvist, M., Beyer, T., Block, M., den Dulk, K., Minten, J., & Lindermans, F. (1998). Adverse events with transvenous implantable cardioverter-defibrillators. A prospective multicenter study. Circulation, 98, 663–670.CrossRef
25.
Zurück zum Zitat Gradaus, R., Block, M., Brachmann, J., Breithardt, G., Huber, H. G., Jung, W., et al. (2003). Mortality, morbidity and complications in 3344 patients with implantable cardioverter defibrillators: results from the German ICD registry EURID. PACE, 26, 1511–1518.CrossRef Gradaus, R., Block, M., Brachmann, J., Breithardt, G., Huber, H. G., Jung, W., et al. (2003). Mortality, morbidity and complications in 3344 patients with implantable cardioverter defibrillators: results from the German ICD registry EURID. PACE, 26, 1511–1518.CrossRef
26.
Zurück zum Zitat Kadish, A., Dyer, A., James, P., et al. (2004). Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy (DEFINITE). The New England Journal of Medicine, 350, 2151–2158.CrossRef Kadish, A., Dyer, A., James, P., et al. (2004). Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy (DEFINITE). The New England Journal of Medicine, 350, 2151–2158.CrossRef
27.
Zurück zum Zitat Al-Khatib, S., Sanders, G., Mark, D., Lee, K. L., Bardy, G. H., Bigger, J. T., et al. (2005). Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomised trial evidence through 2004. American Heart Journal, 149, 1020–1034.CrossRef Al-Khatib, S., Sanders, G., Mark, D., Lee, K. L., Bardy, G. H., Bigger, J. T., et al. (2005). Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomised trial evidence through 2004. American Heart Journal, 149, 1020–1034.CrossRef
28.
Zurück zum Zitat Francia, P., Balla, C., Uccellini, A., & Cappato, R. (2009). Arrhythmia detection in single- and dual-chamber implantable cardioverter defibrillators: the more leads, the better? Journal of Cardiovascular Electrophysiology, 20, 1077–1082.CrossRef Francia, P., Balla, C., Uccellini, A., & Cappato, R. (2009). Arrhythmia detection in single- and dual-chamber implantable cardioverter defibrillators: the more leads, the better? Journal of Cardiovascular Electrophysiology, 20, 1077–1082.CrossRef
29.
Zurück zum Zitat Connolly, S. J., Dorian, P., Roberts, R. S., Gent, M., Bailin, S., Fain, E. S., et al. (2006). Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: a randomized trial. JAMA, 295(2), 165–171.CrossRef Connolly, S. J., Dorian, P., Roberts, R. S., Gent, M., Bailin, S., Fain, E. S., et al. (2006). Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: a randomized trial. JAMA, 295(2), 165–171.CrossRef
30.
Zurück zum Zitat Packer, D., Prutkin, J., Hellkamp, A., Mitchell, B., Bernstein, R., Wood, F., et al. (2012). Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation, 120, 2170–2176.CrossRef Packer, D., Prutkin, J., Hellkamp, A., Mitchell, B., Bernstein, R., Wood, F., et al. (2012). Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation, 120, 2170–2176.CrossRef
31.
Zurück zum Zitat Bhavnani, S. P., Kluger, J., Coleman, C. I., White, C. M., Guertin, D., Shafi, N. A., et al. (2010). The prognostic impact of shocks for clinical and induced arrhytmias on morbidity and mortality among patients with implantable cardioverter-defibrillators. Heart Rhythm, 7, 755–760.CrossRef Bhavnani, S. P., Kluger, J., Coleman, C. I., White, C. M., Guertin, D., Shafi, N. A., et al. (2010). The prognostic impact of shocks for clinical and induced arrhytmias on morbidity and mortality among patients with implantable cardioverter-defibrillators. Heart Rhythm, 7, 755–760.CrossRef
32.
Zurück zum Zitat Mansour, F., & Khairy, P. (2011). Programming ICDs in the modern era beyond out-of-the box settings. Pacing and Clinical Electrophysiology, 34(4), 506–520.CrossRef Mansour, F., & Khairy, P. (2011). Programming ICDs in the modern era beyond out-of-the box settings. Pacing and Clinical Electrophysiology, 34(4), 506–520.CrossRef
33.
Zurück zum Zitat Bänsch, D., Steffgen, F., Grönefeld, G., Wolpert, C., Böcker, D., & Mletzko, R. U. (2004). A prospective trial of a dual versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation, 110, 1022–1029.CrossRef Bänsch, D., Steffgen, F., Grönefeld, G., Wolpert, C., Böcker, D., & Mletzko, R. U. (2004). A prospective trial of a dual versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation, 110, 1022–1029.CrossRef
34.
Zurück zum Zitat Sadoul, N., Mletzko, R., Anselme, F., Bowes, R., Schöls, W., Kouakam, C., et al. (2005). Incidence and clinical relevance of slow ventricular tachycardia in implantable cardioverter-defibrillator recipients. Circulation, 112, 946–953.CrossRef Sadoul, N., Mletzko, R., Anselme, F., Bowes, R., Schöls, W., Kouakam, C., et al. (2005). Incidence and clinical relevance of slow ventricular tachycardia in implantable cardioverter-defibrillator recipients. Circulation, 112, 946–953.CrossRef
35.
Zurück zum Zitat Bänsch, D., Castrucci, M., Böcker, D., Breithardt, G., & Block, M. (2000). Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance. Journal of the American College of Cardiology, 36, 557–565.CrossRef Bänsch, D., Castrucci, M., Böcker, D., Breithardt, G., & Block, M. (2000). Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance. Journal of the American College of Cardiology, 36, 557–565.CrossRef
36.
Zurück zum Zitat Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol; 52:1111–1121 Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol; 52:1111–1121
Metadaten
Titel
Single-chamber ICD, single-zone therapy in primary and secondary prevention patients: the simpler the better?
verfasst von
S. González-Enríquez
F. Rodríguez-Entem
V. Expósito
C. Castrillo-Bustamante
A. Canteli
A. Solloso
I. Madrazo
J. J. Olalla
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 3/2012
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-012-9735-9

Weitere Artikel der Ausgabe 3/2012

Journal of Interventional Cardiac Electrophysiology 3/2012 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.